Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baum M., Houghton J., Riley D. Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group. Acta Oncol. 1992;31(2):251–257. doi: 10.3109/02841869209088911. [DOI] [PubMed] [Google Scholar]
- Catherino W. H., Jordan V. C. A risk-benefit assessment of tamoxifen therapy. Drug Saf. 1993 May;8(5):381–397. doi: 10.2165/00002018-199308050-00005. [DOI] [PubMed] [Google Scholar]
- Powles T. J., Hickish T., Kanis J. A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996 Jan;14(1):78–84. doi: 10.1200/JCO.1996.14.1.78. [DOI] [PubMed] [Google Scholar]
- Rosen P. P., Groshen S., Kinne D. W., Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993 Nov;11(11):2090–2100. doi: 10.1200/JCO.1993.11.11.2090. [DOI] [PubMed] [Google Scholar]
- Rosner D., Lane W. W. Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy. Cancer. 1990 Jul 15;66(2):199–205. doi: 10.1002/1097-0142(19900715)66:2<199::aid-cncr2820660202>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
- Rutqvist L. E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995 May 3;87(9):645–651. doi: 10.1093/jnci/87.9.645. [DOI] [PubMed] [Google Scholar]